交泰丸治疗非酒精性脂肪肝的临床研究

Clinical Observation of Jiaotai Pill in Treatment of Nonalcoholic Fatty Liver Disease

目的观察交泰丸治疗非酒精性脂肪肝(NAFLD)的疗效。方法将60例NAFLD患者随机分为对照组和治疗组,两组在同等生活行为方式干预基础上分别口服力平之和交泰丸治疗,疗程均为3个月,观察两组的临床疗效及治疗前后的体重、肝功能(ALT、AST、γ-GT)、血脂(TC、TG、HDL-C、LDL-C)、游离脂肪酸(FFA)、内脏脂肪素(Visfatin)、胰岛素抵抗指数(HOMA-RI)、肝脏B超的变化。结果治疗组总有效率优于对照组(P<0.05);治疗组体重、血脂、FFA、Visfatin及HOMA-RI均较本组治疗前下降(P<0.05或P<0.01),肝脏B超显示脂肪变性减轻(P<0.05),与对照组比较,差异均有统计学意义(P<0.05,P<0.01)。结论交泰丸治疗NAFLD疗效肯定,能减轻NAFLD患者的体重,改善脂质代谢紊乱,降低血清Visfatin,减轻肝脏脂肪变性,作用机制可能与改善胰岛素抵抗有关。

Objective To analysis the clinical efficacy of Jiaotai pill in treatment of nonalcoholic fatty liver disease（NAFLD）. Methods 60 patients with NAFLD were randomly divided into treatment group and the control group. Two groups were given the same life intervention, plus lipantyl and Jiaotai pill respectively. Clinicial efficacy body weight, hepatic function, blood lipids includingtotal cholesterol （ TC）, triglyceride （ TG）, high density lipoprotein - cholesterol （ HDL - C） and low density lipoprotein - cholesterol （ LDL - C）, plasma levels of free fatty acid （ FFA）, homeostasis model assessment - insulin resistance index（ HOMA - RI）, serum Visfatin and liver ultrasonic were detected before and at the end of the three months＇ treatment. Results Total effective rate of treatment group was superior to that of control group（ P 〈 0.05 ）. Body weight, blood lipids ,FFA,serum Visfatin and HOMA -RI of treatment group were decreased significantly（ P 〈 0.05, P 〈 0.01 ）. Liver ultrasonic of treatment group was also improved significantly（ P 〈 0.05 ）. Compared with control group, the differences were statistically significant（ P 〈 0.05, P 〈 0.01 ）. Conclusion Jiaotai pill in treatment of NAFLD has significantly clinical efficacy, it is suggested that body weight, disturbances of lipids metabolism and hepatic fattydegeneration were improved. The therapeutic mechanism might be related to improving insulin resistance.